Hexahydrocurcumin(Synonyms: 六氢姜黄素)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Hexahydrocurcumin (Synonyms: 六氢姜黄素) 纯度: 99.70%

Hexahydrocurcumin 是姜黄素的主要代谢产物之一，是一种选择性的口服活性 COX-2 抑制剂，对 COX-1 无活性。Hexahydrocurcumin 具有抗氧化，抗癌和抗炎的作用。

Hexahydrocurcumin(Synonyms: 六氢姜黄素)

Hexahydrocurcumin Chemical Structure

CAS No. : 36062-05-2

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥4400 In-stock
5 mg ￥4000 In-stock
10 mg   询价  
50 mg   询价  

* Please select Quantity before adding items.

Hexahydrocurcumin 相关产品

•相关化合物库:

  • Natural Product Library Plus
  • Bioactive Compound Library Plus
  • Immunology/Inflammation Compound Library
  • Metabolism/Protease Compound Library
  • NF-κB Signaling Compound Library
  • Stem Cell Signaling Compound Library
  • Natural Product Library
  • Anti-Cancer Compound Library
  • Anti-Aging Compound Library
  • Antioxidants Compound Library
  • Oxygen Sensing Compound Library
  • Ferroptosis Compound Library
  • Medicine Food Homology Compound Library
  • Phenols Library
  • Pyroptosis Compound Library
  • Orally Active Compound Library
  • Traditional Chinese Medicine Monomer Library
  • Anti-Pancreatic Cancer Compound Library
  • Mitochondria-Targeted Compound Library
  • Food-Sourced Compound Library
  • Anti-Colorectal Cancer Compound Library

生物活性

Hexahydrocurcumin is one of the major metabolites of curcumin and a selective, orally active COX-2 inhibitor. Hexahydrocurcumin is inactive against COX-1. Hexahydrocurcumin has antioxidant, anticancer and anti-inflammatory activities[1][2].

IC50 & Target[1]

COX-2

 

体外研究
(In Vitro)

Hexahydrocurcumin (0-25 μM; 24-48 hours; HT-29 cells) treatment significantly decreased the viability of HT-29 colon cancer cells in a time- and concentration-dependent. The respective IC50 values for 24 and 48 h of Hexahydrocurcumin exposureare 77.05 and 56.95, respectively[1].
Hexahydrocurcumin (0-25 μM; 24-48 hours; HT-29 cells) combined with 5-fluorouracil (5-FU; 5 µM) markedly reduces the COX-2 expression. The level of COX-1 is not altered[1].
Hexahydrocurcumin (0-25 μM; 24-48 hours; HT-29 cells) combined with 5-fluorouracil (5-FU; 5 µM) markedly reduces the COX-2 protein. The level of COX-1 protein is not altered[1].
Hexahydrocurcumin (7-14 μM; 24 hours) attenuates lipopolysaccharide (LPS)-elicited increase of prostaglandin E2 (PGE2) in murine macrophages (RAW 264.7) in a concentration-dependent manner[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: HT-29 cells
Concentration: 0 µM, 5 µM, 10 µM, 25 µM
Incubation Time: 24 hours or 48 hours
Result: Significantly decreased the viability of HT-29 colon cancer cells.

RT-PCR[1]

Cell Line: HT-29 cells
Concentration: 25 µM
Incubation Time: 24 hours
Result: Combined with 5-fluorouracil (5-FU; 5 µM) markedly reduced the COX-2 expression.

Western Blot Analysis[1]

Cell Line: HT-29 cells
Concentration: 25 µM
Incubation Time: 24 hours
Result: Combined with 5-fluorouracil (5-FU; 5 µM) markedly reduced the COX-2 protein.

体内研究
(In Vivo)

Hexahydrocurcumin (50 mg/kg; oral administration; daily; for 16 weeks; male Wistar rats) treatment significantly reduces the numbers of aberrant crypt foci (ACF) in colon cancer rats. Hexahydrocurcumin also markedly decreases COX-2 protein expression. The levels of COX-1 protein is not different from normal rats[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Wistar rats (100-120 g) injected with dimethylhydrazine (DMH)[3]
Dosage: 50 mg/kg
Administration: Oral administration; daily; for 16 weeks
Result: Significantly reduced the numbers of ACF in colon cancer rats. Also markedly decreased COX-2 protein expression.

分子量

374.43

Formula

C21H26O6
CAS 号

36062-05-2
中文名称

六氢姜黄素
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 100 mg/mL (267.07 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.6707 mL 13.3536 mL 26.7073 mL
5 mM 0.5341 mL 2.6707 mL 5.3415 mL
10 mM 0.2671 mL 1.3354 mL 2.6707 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (6.68 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (6.68 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (6.68 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (6.68 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
  • 3.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (6.68 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (6.68 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Srimuangwong K, et al. Hexahydrocurcumin enhances inhibitory effect of 5-fluorouracil on HT-29 human colon cancer cells. World J Gastroenterol. 2012 May 21;18(19):2383-9.

    [2]. Li F, et al. In vitro antioxidant and anti-inflammatory activities of 1-dehydro-[6]-gingerdione, 6-shogaol, 6-dehydroshogaol and hexahydrocurcumin. Food Chem. 2012 Nov 15;135(2):332-7.

    [3]. Srimuangwong K, et al. Effects of hexahydrocurcumin in combination with 5-fluorouracil on dimethylhydrazine-induced colon cancer in rats. World J Gastroenterol. 2012 Dec 21;18(47):6951-9.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务